ABK Biomedical has raised US$35m in a Series D led by J.P. Morgan Life Sciences Private Capital to support Eye90 microspheres commercialisation and scaling.
Existing investors F-Prime, Santé Ventures, Eight Roads Ventures and a significant undisclosed medical device company also joined the round.
ABK said proceeds will fund ongoing clinical operations, prepare for Eye90 microspheres’ market launch, advance product innovation and expand manufacturing and supply chain capacity.
Eye90 microspheres, a Y90 (yttrium-90) radioembolisation therapy designed to be imageable during treatment, has Breakthrough Device Designation from the FDA.
The company is running the Route90 pivotal study under an FDA IDE to evaluate safety and effectiveness in liver cancer.
J.P. Morgan Life Sciences’ managing partner Joe Siletto said the team has been impressed with ABK’s progress since 2019 and highlighted Eye90’s breakthrough status and advancing Route90 trial.
ABK chief executive Mike Mangano said the oversubscribed raise strengthens plans to complete Route90 and prepare for commercial launch, while F-Prime’s Ketan Patel said the product’s design, delivery system and supply chain position it well in the fast-growing Y90 interventional oncology segment.
ABK notes Eye90 microspheres is an investigational device and is not approved outside authorised clinical trials.
